# CAR-T Immunotherapy Targeting CD19- ALL

> **NCT04016129** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 100 (estimated)

## Conditions studied

- B-cell Leukemia

## Interventions

- **BIOLOGICAL:** 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR

## Key facts

- **NCT ID:** NCT04016129
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2028-07-15
- **Final completion:** 2029-12-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04016129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04016129, "CAR-T Immunotherapy Targeting CD19- ALL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04016129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*